Literature DB >> 9548556

Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation.

S Darvesh1, D L Grantham, D A Hopkins.   

Abstract

The distribution of the major cholinergic regulatory enzyme acetylcholinesterase (AChE, EC 3.1.1.7) has been extensively studied in the human brain, but the distribution of the closely related enzyme butyrylcholinesterase (BuChE, EC 3.1.1.8) is largely unknown. Because of the importance of BuChE and AChE in Alzheimer's disease, we have studied the distribution of BuChE in the normal human amygdala and hippocampal formation and compared it with that of AChE by using histochemical techniques. In the amygdala, the distribution of BuChE differed significantly from that of AChE in that BuChE was found primarily in neurons and their dendritic processes, whereas AChE was found predominantly in the neuropil. BuChE-positive neurons were present in up to 10% of the neuronal profiles in lateral, basolateral (basal), basomedial (accessory basal), central, cortical, and medial amygdaloid nuclei. AChE was found primarily in the neuropil in these nuclei with only a few AChE-positive neurons. In the hippocampal formation, BuChE was also found in neurons and not in the neuropil, whereas AChE was found in both neurons and in the neuropil. BuChE and AChE neurons were present in the polymorphic layer of the dentate gyrus, as well as the stratum oriens and stratum pyramidale of the hippocampus proper. There was considerable overlap in shapes, sizes, and numbers of BuChE- and AChE-positive neurons, suggesting that the enzymes were colocalized in neurons of the hippocampal formation. The distinct distribution of BuChE suggests that it may have specific functions including coregulation of cholinergic and noncholinergic neurotransmission in human amygdala and hippocampal formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548556

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  33 in total

1.  Synthesis and preliminary evaluation of piperidinyl and pyrrolidinyl iodobenzoates as imaging agents for butyrylcholinesterase.

Authors:  Ian R Macdonald; G Andrew Reid; E Eric Joy; Ian R Pottie; Gilbert Matte; Steven Burrell; George Mawko; Earl Martin; Sultan Darvesh
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

2.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

Review 3.  Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.

Authors:  George T Grossberg
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 4.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

5.  Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.

Authors:  Yoko Furukawa-Hibi; Tursun Alkam; Atsumi Nitta; Akihiro Matsuyama; Hiroyuki Mizoguchi; Kazuhiko Suzuki; Saliha Moussaoui; Qian-Sheng Yu; Nigel H Greig; Taku Nagai; Kiyofumi Yamada
Journal:  Behav Brain Res       Date:  2011-07-27       Impact factor: 3.332

6.  Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease.

Authors:  Davide V Moretti
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

Review 7.  Physiological roles for butyrylcholinesterase: A BChE-ghrelin axis.

Authors:  Stephen Brimijoin; Vicky Ping Chen; Yuan-Ping Pang; Liyi Geng; Yang Gao
Journal:  Chem Biol Interact       Date:  2016-02-23       Impact factor: 5.192

Review 8.  Neurochemistry of the Anterior Thalamic Nuclei.

Authors:  Witold Żakowski
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

9.  Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.

Authors:  Mohammad A Kamal; Peter Klein; Weiming Luo; Yazhou Li; Harold W Holloway; David Tweedie; Nigel H Greig
Journal:  Neurochem Res       Date:  2007-11-06       Impact factor: 3.996

10.  Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion.

Authors:  A Johansen; E-M D Nielsen; G Andersen; Y H Hamid; D P Jensen; C Glümer; T Drivsholm; K Borch-Johnsen; T Jørgensen; T Hansen; O Pedersen
Journal:  Diabetologia       Date:  2004-07-17       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.